Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats

British Journal of Pharmacology

Volumn 162, Issue 1, 2011, Pages 163-174

  Komers, R ^a   Oyama, T T ^a   Beard, D R ^b   Anderson, S ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

diabetic nephropathy; effective renal plasma flow; fasudil; myosin light chain; Rho associated kinase; RhoA GTPase; ruboxistaurin; Y27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; LOSARTAN; MYOSIN LIGHT CHAIN; PROTEIN KINASE C BETA; RHO KINASE; RUBOXISTAURIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; INHIBITION KINETICS; KIDNEY BLOOD FLOW; KIDNEY HOMOGENATE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STREPTOZOCIN DIABETES; VASODILATATION;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; HEMODYNAMICS; INDOLES; KIDNEY; LOSARTAN; MALEIMIDES; RATS; RHO-ASSOCIATED KINASES; STREPTOZOCIN;

EID: 78650162527     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01031.x     Document Type: Article

References (52)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC). Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, et al. (1996). Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271: 20246-20249. (Pubitemid 26281788)
3. Anderson S, (1998). Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab 24: 406-411.
4. Anderson S, Komers R, (2004). Renal hemodynamics in experimental diabetes mellitus. In:, Mogensen CEN, (ed.). The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers: Norwell, MA, pp. 363-382.
5. Anderson S, Jung FF, Ingelfinger JR, (1993). Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265: F477-F486. (Pubitemid 23325866)
6. Banes-Berceli AK, Shaw S, Ma G, Brands M, Eaton DC, Stern DM, et al. (2006). Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 291: F116-F121.
7. Bauer J, Parekh N, (2003). Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. Kidney Int 63: 2178-2186.
8. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM, et al. (2003). Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation 108: 342-347.
9. Cavarape A, Bauer J, Bartoli E, Endlich K, Parekh N, (2003a). Effects of angiotensin II, arginine vasopressin and tromboxane A2 in renal vascular bed: role of rho-kinase. Nephrol Dial Transplant 18: 1764-1769.
10. Cavarape A, Endlich N, Assaloni R, Bartoli E, Steinhausen M, Parekh N, et al. (2003b). Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 14: 37-45.
11. Cherney DZ, Konvalinka A, Zinman B, Diamandis EP, Soosaipillai A, Reich H, et al. (2009). Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 32: 91-93.
12. Das Evcimen N, King GL, (2007). The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55: 498-510.
13. Fukumoto Y, Mohri M, Inokuchi K, Ito A, Hirakawa Y, Masumoto A, et al. (2007). Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 49: 117-121.
14. Hamid SA, Bower HS, Baxter GF, (2007). Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292: H2598-H2606.
15. Hannedouche TP, Delgado AG, Gnionsahe DA, Boitard C, Lacour B, Grunfeld J-P, (1990). Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int 37: 1126-1133.
16. Holinstat M, Mehta D, Kozasa T, Minshall RD, Malik AB, (2003). Protein kinase Calpha-induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement. J Biol Chem 278: 28793-28798.
17. Inscho EW, Cook AK, Webb RC, Jin LM, (2009). Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter. Am J Physiol Renal Physiol 296: F590-F597.
18. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. (1996). Amelioration of vascular dysfunctions in diabetic rats by an oral PKCb inhibitor. Science 272: 728-731.
19. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H, (2006). Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47: 1075-1083.
20. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T, (2003). Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 64: 2009-2019.
21. Kanda T, Hayashi K, Wakino S, Homma K, Yoshioka K, Hasegawa K, et al. (2005). Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension 45: 724-729.
22. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, et al. (2002). Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39: 245-250.
23. Kawamura H, Yokote K, Asaumi S, Kobayashi K, Fujimoto M, Maezawa Y, et al. (2004). High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 276-281.
24. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, et al. (2003). Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52: 512-518.
25. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR, (2008). Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57: 714-723.
26. Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S, (2000). Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats. Hypertension 34: 655-661.
27. Komers R, Schutzer WE, Reed JF, Lindsley JN, Oyama TT, Buck DC, et al. (2006). Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes 55: 1651-1659.
28. Komers R, Oyama TT, Beard DR, Tikellis C, Xu B, Lotspeich DF, et al. (2010). Effect of rho kinase inhibition on the development of nephropathy in uninephrectomized diabetic rats. Kidney Int (in press).
29. Koya D, King GL, (1998). Protein kinase C activation and the development of diabetic complications. Diabetes 47: 859-866.
30. Koya D, Jirousek MR, Lin Y-W, Ishii H, Kuboki K, King GL, (1997). Characterization of protein kinase C-b isoform activation on the gene expression of transforming factor-b, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100: 115-126.
31. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, et al. (2000). Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439-447.
32. Loirand G, Rolli-Derkinderen M, Pacaud P, (2005). RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 288: H1051-H1056.
33. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG, (2009). Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52: 691-697.
34. Massey AR, Miao L, Smith BN, Liu J, Kusaka I, Zhang JH, et al. (2003). Increased RhoA translocation in renal cortex of diabetic rats. Life Sci 72: 2943-2952.
35. Mehta D, Rahman A, Malik AB, (2001). Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J Biol Chem 276: 22614-22620.
36. Miao L, Calvert JW, Tang J, Zhang JH, (2002). Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats. Life Sci 71: 1175-1185.
37. Nakamura A, Hayashi K, Ozawa Y, Fujiwara K, Okubo K, Kanda T, et al. (2003). Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone. J Vasc Res 40: 244-251.
38. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, et al. (2004). Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 22: 1787-1796.
39. Numabe A, Komatsu K, Frohlich ED, (1994). Effects of ANG-converting enzyme and alpha 1-adrenoceptor inhibition on intrarenal hemodynamics in SHR. Am J Physiol 266: R1437-R1442.
40. Ozawa Y, Kobori H, (2007). Crucial role of Rho-nuclear factor kappa beta axis in angiotensin ii-induced renal injury. Am J Physiol Renal Physiol 293: F100-F109.
41. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, et al. (2008). RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 57: 1683-1692.
42. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, et al. (2003). Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 64: 565-571.
43. Rikitake Y, Liao JK, (2005). Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 111: 3261-3268.
44. Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, et al. (2004). Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 110: 51-57.
45. Somlyo AP, Somlyo AV, (2003). Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83: 1325-1358.
46. Strassheim D, May LG, Varker KA, Puhl HL, Phelps SH, Porter RA, et al. (1999). M3 muscarinic acetylcholine receptors regulate cytoplasmic myosin by a process involving RhoA and requiring conventional protein kinase C isoforms. J Biol Chem 274: 18675-18685.
47. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, et al. (2006). Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 17: 2193-2201.
48. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW, (2005). The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686-2690.
49. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. (1997). Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994.
50. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, et al. (2009). ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res 104: 531-540.
51. Winaver J, Ovcharenko E, Rubinstein I, Gurbanov K, Pollesello P, Bishara B, et al. (2006). Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 290: H2007-H2014.
52. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM, (1986). Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930.